{
  "id": 4728951,
  "title": "Medicare Update: Hundreds of Thousands Get GLP-1 Drugs for Just $50",
  "url": "https://urgent.news/2026/08/31/medicare-update-hundreds-of-thousands-get-glp-1-drugs-for-just-50",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-31T22:11:05.000Z",
  "source": {
    "name": "Newsweek",
    "slug": "newsweek",
    "url": "https://www.newsweek.com/medicare-update-hundreds-of-thousands-get-glp-1-drugs-for-just-50-12388495"
  },
  "original_language": "en",
  "account": "More than 600,000 Medicare beneficiaries have enrolled in a new federal program that caps monthly costs at $50 for GLP-1 weight-loss medications, according to Centers for Medicare & Medicaid Services (CMS) Administrator Dr. Mehmet Oz. The enrollment milestone was reached within the first two months of the program's launch on July 1, 2024. These obesity treatments have previously been financially inaccessible for many seniors due to their high price tags.\n\nMichael Ryan, a finance expert, explained that the program transforms access to these drugs from an expensive and unpredictable monthly expense into a simple $50 decision. The Medicare GLP-1 Bridge program covers select medications such as Wegovy, Zepbound, and Foundayo, but it is only temporary, running until December 31, 2027.\n\nThe program aims to provide innovative but costly treatments at a predictable cost, while evaluating how broader coverage could impact health outcomes and Medicare spending. Eligible beneficiaries must have Medicare Part D prescription drug coverage and meet clinical criteria based on body mass index (BMI) and specific medical conditions.",
  "summary": "Before the new program, patients often faced out-of-pocket expenses that could exceed $1,000 per month.",
  "key_points": [
    "Over 600,000 Medicare beneficiaries enrolled in $50 cap program for GLP-1 drugs by July 2024.",
    "Program covers Wegovy, Zepbound, and Foundayo, but temporary until Dec 31, 2027.",
    "Aims to provide predictable costs while evaluating broader coverage impacts."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}